DEXCOM, INC. (NASDAQ: DXCM) INVESTOR ALERT Investors With Large Losses in DexCom, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Core Viewpoint - A shareholder has filed a securities class action lawsuit against DexCom, Inc. for alleged misrepresentations regarding the accuracy and functionality of its Dexcom G7 continuous glucose monitoring system, affecting investors who purchased securities between January 8, 2024, and September 17, 2025 [1][2]. Group 1 - The lawsuit claims that the defendants made false statements about the reliability and enhancements of the Dexcom G7 system, as well as the company's manufacturing capabilities [2]. - Investors who wish to serve as lead plaintiffs must file by December 26, 2025, but participation in any recovery does not require serving as lead plaintiff [3]. - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented both individual investors and large pension funds [4].